Weekly Digest – September 2025 Weekly Digest – September 2025 24 September 2025: Enhertu plus Pertuzumab granted priority review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer The FDA has granted priority review to Enhertu […]
Weekly Digest – September 2025 Weekly Digest – September 2025 22 September 2025: Huadong Medicine’s CDH17-targeted ADC HDM2017 IND application received FDA approval in the US The U.S. FDA approved Huadong Medicine’s IND application for HDM2017, a CDH17-targeted ADC, allowing […]
Weekly Digest – September 2025 Weekly Digest – September 2025 25 September 2025: Qurient and Synaffix partner to develop next-generation dual-payload ADCs Qurient entered into a licensing agreement with Synaffix (a Lonza subsidiary) to develop next-generation dual-payload ADCs, integrating Qurient’s […]
Weekly Digest – September 2025 Weekly Digest – September 2025 23 September 2025: TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer TegMine Therapeutics entered a strategic R&D collaboration with Boehringer Ingelheim to advance […]
Weekly Digest – September 2025 Weekly Digest – September 2025 22 September 2025: Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration Mabwell Bioscience, Insilico Medicine, and ChemExpress formed a strategic collaboration to jointly develop […]
Weekly Digest – September 2025 Weekly Digest – September 2025 24 September 2025: Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811) Hengrui Pharma granted Glenmark exclusive rights (excluding major markets like China, US, […]
